Sjögren's disease & overlap diseases
Clinical impact of anti-SSA antigenic specificity on disease activity and patient-reported outcomes in primary Sjögren's disease: a real-life cohort study
Authors' conclusion
Anti-SSA antigenic specificity delineates biologically and clinically distinct phenotypes within SjD.
Study context
- Population
- Anti-SSA-positive Sjögren's disease (SjD) patients fulfilling 2016 ACR/EULAR criteria, real-life clinical practice
- Participants
- 279 patients
- Exposure
- Isolated anti-Ro52 vs isolated anti-Ro60 vs double anti-Ro52/anti-Ro60 vs triple anti-Ro52/anti-Ro60/anti-La/SSB positivity
- Outcome
- Systemic, serological and patient-reported phenotypes (ESSDAI, IgG, C3, C4, ESSPRI and subdomains)
- Follow-up
- Study entry
Methodological detailsreal-life cohort, adjusted analyses (modified Poisson regression, general linear models)
- Real-life cohort
- Adjusted analyses (modified Poisson regression, general linear models)
Main finding
As reported in the abstract
| Group | Value | IgG | ESSPRI |
|---|---|---|---|
| Triple-positive | median 3 (IQR 1–6) | 1497 [1180-1790] mg/dL | |
| Isolated anti-Ro60 | 0 (IQR 0–0) | 6.08 [0.52] |
Value
Triple-positivemedian 3 (IQR 1–6)
Isolated anti-Ro600 (IQR 0–0)
IgG
Triple-positive1497 [1180-1790] mg/dL
Isolated anti-Ro60— not stated in the abstract
ESSPRI
Triple-positive— not stated in the abstract
Isolated anti-Ro606.08 [0.52]
- Triple-positive: highest ESSDAI and IgG, enriched for haematologic, lymphoid, glandular and biological domains
- P < 0.001
- Isolated anti-Ro60: mildest systemic activity yet highest patient-reported burden (ESSPRI)
- P < 0.01
- Adjusted: only triple-positive independently associated with increased systemic activity and B-cell hyperactivity
- all p<0.05
Observational data: associations, not effects.
Further findings
Combined ESSDAI/ESSPRI stratification
- Low-activity/high-symptom cases predominated, enriched among isolated anti-Ro52 and anti-Ro60
Original publication
Clinical impact of anti-SSA antigenic specificity on disease activity and patient-reported outcomes in primary Sjögren's disease: a real-life cohort study. Clin Exp Rheumatol. Published 18 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →